AC Immune’s Parkinson’s Vaccine Shows Strong Safety and Immunogenicity in Phase 2 Trial
Event summary
- AC Immune’s ACI-7104 met all primary safety and immunogenicity endpoints in Part 1 of the VacSYn Phase 2 trial for early-stage Parkinson’s disease.
- 100% of patients developed antibodies against the target antigen after three immunizations, with robust antibody penetration into cerebrospinal fluid.
- Exploratory analyses showed preliminary signals of target engagement and correlations between antibody levels and disease activity measures.
- Discussions with the FDA on the future development path are planned for early 2027.
The big picture
AC Immune’s positive Phase 2 data for ACI-7104 reinforces the potential of active immunotherapies in neurodegenerative diseases. The strong immunogenicity and safety profile position the company favorably as it navigates regulatory discussions and prepares for larger-scale clinical validation. The broader biotech sector continues to focus on targeting misfolded proteins, with AC Immune’s proprietary pipeline offering a competitive edge in Parkinson’s and other neurodegenerative conditions.
What we're watching
- Regulatory Pathway
- Whether the FDA discussions in early 2027 will accelerate or delay the transition to Part 2 of the VacSYn trial.
- Clinical Efficacy
- How the exploratory signals of target engagement and disease activity correlations will translate into clinical outcomes in Part 2.
- Competitive Positioning
- The pace at which AC Immune can differentiate ACI-7104 in the crowded Parkinson’s disease therapeutic landscape.